<DOC>
	<DOC>NCT00981318</DOC>
	<brief_summary>This is a study to assess the response of lopinavir/ritonavir plus maraviroc (with no nucleoside medications) in HIV patients failing their initial antiviral therapy.</brief_summary>
	<brief_title>Pilot Assessment of Lopinavir/Ritonavir and Maraviroc</brief_title>
	<detailed_description>As long-term toxicity to many of the nucleoside medications have become known, interest has increased in treatment regimens that do not use these medications. This study is to assess the response of one such "nucleoside-sparing" therapy in patients who are showing failure to their initial nucleoside-containing treatment regimen.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>HIV viral load &gt; 1,000 on current antiviral medications No resistance to study medications Over 18 years of age Hepatitis B coinfection Pregnancy Previous therapy with either of the study medications Ongoing substance abuse Significant history of other physical disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>treatment experienced</keyword>
</DOC>